Finance

Beta
Lists
ALMKT:EPA
Mauna Kea Technologies SA
0,17 €
-1,49%
(-0,0026) 1D
3 ივნ, 17:35:09 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ALMKT...
Open
0,18 €
High
0,18 €
Low
0,17 €
Mkt. cap
33,70 მლნ.
Avg. vol.
632,53 ათ.
Volume
450,82 ათ.
52-wk high
0,23 €
52-wk low
0,07 €
EPS
-0,14 €
Shares outstanding
192,10 მლნ.
No. of employees
61
Open
0,18 €
High
0,18 €
Low
0,17 €
Mkt. cap
33,70 მლნ.
Avg. vol.
632,53 ათ.
Volume
450,82 ათ.
52-wk high
0,23 €
52-wk low
0,07 €
EPS
-0,14 €
Shares outstanding
192,10 მლნ.
No. of employees
61
News stories
From sources across the web
Business Wire
Business Wire
·
23 წუთის წინ
Intuit CFO Sandeep Aujla to Present at the Nasdaq Investor Conference
Stock Titan
Stock Titan
·
5 წუთის წინ
New Nektar hires get 11,900 stock options with $69.49 strike
The Commercial Appeal
The Commercial Appeal
·
1 საათის წინ
FedEx Freight celebrates debut on New York Stock Exchange
Yahoo Finance
Yahoo Finance
·
6 საათის წინ
Is Equinix Stock Underperforming the Nasdaq?
Profile
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts. The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues. Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time. Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
About Mauna Kea Technologies SA
CEOსაჩა ლოისო
Employees61
Founded2000
Headquarters-
SectorMedical device
Websitemaunakeatech.com
Last report
15 იან. 2026
Fiscal period
Q4 2025
EPS / Est. (EUR)
- / -
Revenue / Est. (EUR)
2,44 მლნ. / -
Fiscal Q4 2025 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
მარ. 2025
ივნ. 2025
სექ. 2025
დეკ. 2025
Revenue
2,02 მლნ.
2,02 მლნ.
2,44 მლნ.
2,44 მლნ.
Cost of goods sold
396,00 ათ.
396,00 ათ.
528,00 ათ.
528,00 ათ.
Cost of revenue
396,00 ათ.
396,00 ათ.
528,00 ათ.
528,00 ათ.
Research and development expenses
818,50 ათ.
818,50 ათ.
861,00 ათ.
861,00 ათ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,90 მლნ.
1,90 მლნ.
1,89 მლნ.
1,89 მლნ.
Operating expense
3,02 მლნ.
3,02 მლნ.
3,11 მლნ.
3,11 მლნ.
Total operating expenses
3,41 მლნ.
3,41 მლნ.
3,64 მლნ.
3,64 მლნ.
Operating income
-1,40 მლნ.
-1,40 მლნ.
-1,20 მლნ.
-1,20 მლნ.
Other non operating income
-695,00 ათ.
-695,00 ათ.
10,84 მლნ.
10,84 მლნ.
EBT including unusual items
-2,31 მლნ.
-2,31 მლნ.
7,69 მლნ.
7,69 მლნ.
EBT excluding unusual items
-2,20 მლნ.
-2,20 მლნ.
8,06 მლნ.
8,06 მლნ.
Income tax expense
28,00 ათ.
28,00 ათ.
-35,50 ათ.
-35,50 ათ.
Effective tax rate
-1,21%
-1,21%
-0,46%
-0,46%
Other operating expenses
83,00 ათ.
83,00 ათ.
92,00 ათ.
92,00 ათ.
Net income
-2,33 მლნ.
-2,33 მლნ.
7,72 მლნ.
7,72 მლნ.
Net profit margin
-115,83%
-115,83%
316,50%
316,50%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-6,50 ათ.
-6,50 ათ.
-490,50 ათ.
-490,50 ათ.
Net interest expenses
-6,50 ათ.
-6,50 ათ.
-490,50 ათ.
-490,50 ათ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-1,35 მლნ.
-1,35 მლნ.
-1,11 მლნ.
-1,11 მლნ.
Gain or loss from assets sale
-
-
281,00 ათ.
281,00 ათ.
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer